Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631834 | 0.85 | MAPT (0.68) | MAPTALDH1A1GFERSMN1; SMN2TP53 | |
| SCHEMBL20708157 | 0.84 | JAK3 (0.52) | ADAMTS5MMP2MAPTALDH1A1GFER | |
| SCHEMBL28747907 | 0.81 | MAPT (0.50) | MAPTALDH1A1GFERSMN1; SMN2MAPK1 | |
| SCHEMBL11299182 | 0.81 | MAPT (0.51) | MAPTALDH1A1GFERSMN1; SMN2TP53 | |
| SCHEMBL4587896 | 0.80 | RAB9A (0.60) | ADAMTS5MMP2MAPTALDH1A1GFER | |
| SCHEMBL632099 | 0.80 | LMNA (0.68) | MAPTALDH1A1GFERSMN1; SMN2HTT | |
| SCHEMBL20708368 | 0.79 | ADAMTS5 (0.62) | ADAMTS5MMP2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20139789 | 0.79 | MAPT (0.56) | ADAMTS5MMP2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13688215 | 0.79 | MAPT (0.52) | MAPTALDH1A1GFERSMN1; SMN2TP53 | |
| SCHEMBL31381202 | 0.79 | NOTUM (0.63) | ALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | ADAMTS5 1603/4885MMP2 2754/4885MAPT 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.